Patient Square Capital
ABVX icon

Patient Square Capital’s Abivax ABVX Stock Holding History

Patient Square Capital’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$24.1M Buy
243,000
+36,500
+18% +$4.4M 3.84% 6
2026
Q2 		$27.5M Buy
206,500
+85,255
+70% +$9.6M 4.26% 4
2026
Q1 		$13.5M Sell
121,245
-8,755
-7% -$1.04M 2.4% 12
2025
Q4 		$17.5M Sell
130,000
-21,833
-14% -$2.38M 3.75% 6
2025
Q3 		$12.9M Buy
+151,833
New +$9.31M 3.45% 4

Other funds holding ABVX

Helikon Investments
Helikon Investments London, United Kingdom $3.52B AUM 36.83% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $2.08B AUM 157.4% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Patient Square Capital's ABVX Position: Q3 2026 in Review

Patient Square Capital increased its Abivax (ABVX) stake by 18% in Q3 2026, buying an estimated $4.4M and bringing the position to 243,000 shares worth $24.1M. The position accounts for 3.84% of the portfolio, ranked #6.

Patient Square Capital first reported a position in ABVX in Q3 2025 and has held it in 5 quarters since. The position peaked at $27.5M in Q2 2026. 211 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

  • Patient Square Capital held 243,000 shares of Abivax worth $24.1M as of Q3 2026.
  • Patient Square Capital bought 36,500 Abivax shares in Q3 2026, an estimated $4.4M.
  • Abivax made up 3.84% of Patient Square Capital's portfolio in Q3 2026, its #6 holding.
  • Patient Square Capital first reported a position in Abivax in Q3 2025 and has held it in 5 quarters since.
  • Patient Square Capital's Abivax position peaked at $27.5M in Q2 2026.
  • 211 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on Patient Square Capital's 13F filing for Q3 2026, filed 10 Nov 2026.